X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BG-68501 is a small molecule, cyclin-dependent kinase 2 (CDK2) inhibitordrug candidate, which is being evaluated for the treatment of patients with solid tumours.
Lead Product(s): BG-68501,Fulvestrant
Therapeutic Area: Oncology Product Name: BG-68501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2024
Details:
BeiGene partners with NewBridge for the distribution and commercialization activities for BRUKINSA (zanubrutinib) in the MENA region. It is indicated for the treatment of Chronic Lymphocytic Leukemia.
Lead Product(s): Zanubrutinib
Therapeutic Area: Oncology Product Name: Brukinsa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NewBridge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 13, 2024
Details:
BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor, which is being evaluated for the treatment of HR+/HER2 solid tumors including breast, ovarian, and Small Cell Lung Cancer.
Lead Product(s): BG-68501,Fulvestrant
Therapeutic Area: Oncology Product Name: BG-68501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ensem Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
The agreement aims to evaluate the safety and efficacy of Bria-OTS, BriaCell’s next generation immunotherapy, in combination with BeiGene's anti-PD-1 tislelizumab, for metastatic breast cancer.
Lead Product(s): Bria-OTS,Tislelizumab
Therapeutic Area: Oncology Product Name: Bria-OTS
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: BriaCell Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2024
Details:
Glenmark will register and commercialize BeiGene’s, Tevimbra (tislelizumab), in India. It is indicated for adult patients with unresectable or metastatic esophageal squamous cell carcinoma.
Lead Product(s): Tislelizumab
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 21, 2024
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is indicated for the treatment of advanced squamous NSCLC.
Lead Product(s): Tislelizumab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Tevimbra (tislelizumab), now FDA approved, is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc-gamma receptors on macrophages, helping to aid the body’s immune cells to detect and fight with locally advanced, or metastatic ESCC.
Lead Product(s): Tislelizumab
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
BeiGene has granted accelerated approval to Brukinsa (zanubrutinib), BTK Inhibitor for the treatment of adult patients with relapsed or refractory follicular lymphoma, in combination with the anti-CD20 monoclonal antibody obinutuzumab.
Lead Product(s): Zanubrutinib,Obinutuzumab
Therapeutic Area: Oncology Product Name: Brukinsa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Brukinsa (zanubrutinib) is a small molecule inhibitor of BTK designed to deliver complete and sustained inhibition of the BTK protein. It is being evaluated for the treatment of relapsed/refractory chronic lymphocytic leukemia.
Lead Product(s): Zanubrutinib
Therapeutic Area: Oncology Product Name: Brukinsa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is being evaluated for the treatment of first-line gastric or gastroesophageal junction cancers.
Lead Product(s): Tislelizumab,Carboplatin,Fluoropyrimidine
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
